Paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes exhibit abnormalities in decay accelerating factor (DAF), acetylcholinesterase, and resistance to autologous C5b-9 attack. To investigate the nature of the lesion underlying PNH cells, we examined the relationship of these abnormalities to one another. Analyses of DAF in acetylcholinesterase-negative erythrocytes revealed that these two abnormalities involve functionally independent molecules, coincide precisely in the same cell populations, and are similarly expressed in PNH II and more complement-sensitive PNH III erythrocytes. The DAF and acetylcholinesterase deficiencies contrast with the C3b/C4b receptor (CR1) deficit, which is less profound and similarly distributed in complement-insensitive cell populations. Hemolytic studies showed that defective resistance to autologous C5b-9 attack is mediated by another mechanism. Whereas reconstitution of PNH II erythrocytes with DAF completely corrected their complement sensitivity, DAF reconstitution of PNH III erythrocytes restored their ability to circumvent C3b uptake but had no effect on their heightened susceptibility to reactive lysis. Assays of complement-insensitive (PNH I) erythrocytes surviving after reactive lysis disclosed partial DAF and acetylcholinesterase deficits. These findings indicate that the PNH lesion involves multiple membrane components and that PNH I erythrocytes are also abnormal. 
Introduction
Paroxysmal nocturnal hemoglobinuria (PNH)' is an acquired disorder in which variable proportions of blood elements sensitive to the lytic action of autologous complement appear in the circulation (reviewed in reference 1). It is thought that the Receivedfor publication 1I September 1986 and in revisedform 26 December 1986.
1. Abbreviations used in this paper: AChE, acetylcholinesterase; C-EDTA, C3-9 reagent; CLS, complement lysis sensitivity; CR1, C3b/C4b receptor, DAF, decay accelerating factor, EhU, human erythrocyte; EhUA, EhuACi, EhUAC14, and EbUAC1423, complement intermediates bearing respective components; FACS, fluorescence-activated cell sorter, NP40, Nonidet-P40 detergent; PNH, paroxysmal nocturnal hemoglobinuria. aberrant circulating cells originate from the clonal proliferation of bone marrow progenitors altered by somatic mutation. Considerable experimental data have shown that their complement sensitivity is due to intrinsic defects in their cell membranes. Two groups of investigators found that they are deficient (2) (3) (4) in a complement regulatory protein termed decay accelerating factor (DAF) (5-11), establishing a molecular basis for their abnormal interaction with the complement system.
Recently, it was observed that purified DAF could be incorporated into cell membranes in vitro (8) and that, once cellassociated, the exogenous DAF could move freely in the plane ofthe membrane and exert its activity. It was shown from studies exploiting this phenomenon that in situ DAF could prevent the assembly of C3 and C5 convertases of both complement pathways on cell surfaces and thereby could protect cells from complement attack. To examine the role of DAF deficiency in the lytic abnormalities of PNH cells, DAF was restored to affected PNH erythrocytes (E'u) (12) . Reconstitution ofthe DAF-deficient PNH Ehu with DAF corrected their excessive C3b uptake. The DAF reconstitution, however, had only a partial effect on acid lysis susceptibility ofthe affected cells. Although physiologic DAF levels were not achieved in these studies, this finding raised the possibility that other membrane defects that could preclude complete correction of the lytic sensitivity by DAF might exist in the PNH cells.
Several alterations have been reported in the membranes of PNH Ehu (1). Affected cells not only take up excessive amounts of C3b, but they are characteristically deficient in membrane acetylcholinesterase (AChE). Additionally, whereas PNH II El', found in some patients, are three-to fivefold more sensitive to complement than normal Ehu, PNH III E'u, present in the majority of patients, are 15-to 25 -fold more sensitive. The PNH III E'u are markedly more susceptible than normal Ehu to bystander lysis by fluid-phase terminal pathway complexes (e.g., C5b-9). There is experimental evidence suggesting that the vulnerability of PNH III Ehu to this passive lysis may be due to a defect in the capacity of the affected cells to restrict insertion and/or polymerization of autologous C9 (13) (14) (15) (16) (17) as well as to a defect in their ability to circumvent uptake of C3b.
Whether DAF and AChE deficiencies overlap in affected PNH Ehu and are separate abnormalities and whether either is involved in the heightened sensitivity of PNH III cells to bystander lysis are not known. The present study was undertaken to investigate the relationship of these three abnormalities in affected PNH Ehu.
Methods
Buffers, reagents, and labeling. Isotonic veronal contained 2.5 mM bar-place of 73 mM NaCl and 2.5% dextrose. Metal-chelating veronal was prepared as isoionic veronal but contained 10 mM EDTA in place of metals. Phosphate-buffered saline (PBS) contained 10 mM sodium phosphate, pH 7.4, and 150 mM NaCi.
Nonidet-P40 detergent (NP40) was purchased from Particle Data, Inc. (Elmhurst, IL), phenylmethylsulfonyl fluoride and Clostridium neuraminidase (type VI) from Sigma Chemical Corp. (St. Louis, MO), and the synthetic elastase inhibitor, Suc-(OMe)-Ala-Ala-Pro-Val-MCA, from Peninsula Laboratories Inc. (Belmont, CA).
Proteins and Ehu were labeled by lodogen (Pierce Chemical Co., Rockford, IL) according to the manufacturer's instructions. In the case ofthe cells, 0.5 mCi 1251I per 109 Ehu was used, and the procedure described in reference 18 followed.
Purified proteins and antibodies. C2 (19) , C4 (20) , C3 (20) , C5 (20) , C6-9 (21), guinea pig Cl (22) , and guinea pig and human C3-9 (C-EDTA) (22) were prepared as described. Cobra venom factor was purified by the method in reference 23.
DAF was isolated from butanol extracts of pooled Ehu stroma as described (8, 9) . The purified product had characteristic mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels (see inset of Fig. 1 (New York Blood Center). Serum containing anti-I cold agglutinin was obtained from patient J.S. with chronic cold agglutinin disease (26) .
Rabbit anti-DAF antibodies were prepared as in reference 8. They were monospecific as assessed by immunoblotting with crude extracts of Ehu stroma. Rabbit anti4(Ehu-associated)-AChE antibodies were a gift of Dr. Lucio Luzzatto (University of Naples, Naples, Italy). Mouse monoclonal anti-DAF antibodies (IAI0, IIH6, and VIIIA7) were obtained as described in reference 9. Hybridomas (AEI and AE2) producing monoclonal anti-(Ehu)AChE antibodies (27) were obtained from the American Tissue Type Collection (Rockville, MD). Monoclonal anti-CR1 antibodies (44D, 57F, 31D, and 57H) (24) and control anti-malaria antibodies (3D1 1, 2G3, 6G2, and 2A10) of appropriate subtypes were prepared as described (28) . Anti-DAF, -CR1, and -malaria monoclonals were purified by (NH4)2SO4 precipitation and DEAE-Sephacel chromatography. Anti-AChE monoclonals were used as ascites fluids.
Fluorescein-isothiocyanate-conjugated goat F(ab')2 anti-mouse Ig and rabbit anti-mouse Ig were from Cappel Laboratories (Cochranville, PA), protein-A agarose suspension from Zymed Labs Inc. (San Francisco, CA), and protein-A Sepharose CL-4B from Pharmacia, Inc. (Piscataway, NJ).
Measurements ofDAF and CRI levels. Levels of DAF and CR1 in Ehe were quantitated by two-site radioimmunometric assays employing the respective monoclonal antibodies as described in references 9 and 25. Ehu samples were lysed with 1% NP40 (at 5 X 109/ml in the case of DAF and 2 X 10'°/ml in the case of CR1), diluted 10-fold (in PBS containing 1 mM phenylmethylsulfonyl fluoride and 50 Ag/ml synthetic elastase inhibitor), and clarified by centrifugation. The amounts of DAF or CR1 in the Ehu samples were determined by reference to standard curves generated using increasing amounts of the respective purified membrane proteins.
Surface expression of DAF on Eh, was assessed by flow cytometry using a fluorescence-activated cell sorter (FACS) (Ortho Diagnostics, Westwood, MA) as described in reference 9. The Ehl (106 cells in 25 ;L of PBS containing 1% bovine serum albumin [BSA] ) were incubated on ice for 30 min with pooled monoclonal anti-DAF antibodies (5 ug/ml each in 25 ,ul of the same buffer) or, as a control, with a mixture of nonrelevant (antimalaria) monoclonal antibodies at the same concentrations. After washing, the Ehu were resuspended to 25 M1 in PBS containing 1% BSA, and incubated on ice for 30 min with an equal volume of a 1:50 dilution of fluorescein-isothiocyanate-goat F(ab')2 anti-mouse Ig. The treated cells were washed again and resuspended to I ml in the same buffer.
Hemolytic assays. Efficiency of classical C3 convertase, C4b2a, assembly on Ehu was assessed as described in reference 12. Ehl were sensitized with rabbit IgM hemolysin to provide 50 Cl fixing sites per cell (29) . After washing, the EhUA (1 X 108/ml in isotonic veronal buffer) were incubated at 30°C for 15 min with Cl at a concentration 10-fold higher than that required for maximum uptake ofC4. Washed EhUACI (1 X 108/ ml in isotonic veronal) were incubated for 15 min at 30°C with increasing concentrations of C4. The number of C4b molecules deposited at each C4 input was determined by employing 1251-labeled C4 in parallel studies. The EhUAC14 (1 X 108/ml in isotonic veronal) bearing increasing numbers of C4b per cell were mixed with C2 adjusted to a concentration 10-fold higher than that giving maximum lysis of EhuACl4 prepared with limited C4 and treated with anti-DAF antibodies. After incubation at 30°C for 5 min, hemolytic activity was developed by addition of 1.8 ml of C3-9 reagent (C-EDTA 1:20 in metal-chelating veronal buffer) and further incubation at 37°C for 60 min.
Complement lysis sensitivity (CLS) of Ehu was assessed as described by Rosse and Dacie (26, 30) . Ehu (2 X 108/ml in isoionic veronal buffer) were mixed at 37°C with an equal volume of anti-I serum (1:50 in 0.15 M NaCl). 5S-gl aliquots ofthe EhU anti-I mixtures were added to increasing volumes of 1:270, 1:90, 1:30, or 1:10 normal human serum. The resulting mixtures were preincubated at 0°C for 30 min, placed at 37°C, and after 1 h isoionic veronal buffer was added, the tubes centrifuged, and lysis read. The relative sensitivity of the cells was expressed in CLS H50 units (26) .
Susceptibility of the Elu to reactive lysis was assessed using cobra venom factor as described in reference 23. Portions (100 Ml) of Ehu (1 X 108/ml in metal-chelating veronal buffer) were mixed with equal volumes offresh human serum diluted 1:4 to 1:64 in the same buffer. Cobra venom factor:Bb complexes, prepared by incubation of cobra venom factor (I mg/ml in isoionic veronal buffer) at 370C for 2 h with an equal volume of (neat) serum, were diluted 1:32 in metal-chelating veronal buffer, and 50-Ml aliquots of the diluted complexes were added to the various Ebu serum mixtures. The reaction tubes were placed at 370C, and after I hr, 4 ml of metal-chelating veronal buffer was added, the tubes centrifuged, and lysis read.
Immunoprecipitation, SDS-PAGE, and autoradiography. The NP40 extract of 109 "'I-surface-labeled Ehu was diluted to I ml with PBS and cleared by rotation at 00C for 30 min with 10% vol/vol protein A-agarose suspension in 15 mM NaCl, 9 mM EDTA, 50 mM Tris, pH 7.4, containing 0.05% NP40 and I mg/ml ovalbumin. After centrifugation, 250-ul aliquots ofthe supernatant were rotated at 00C for 30 min with pooled monoclonal anti-DAF antibodies (IA10, 11H6, and VIIIA7), 5 ug/ml each, individual anti-AChE antibodies (AEI or AE2), 5 usg/ml each, or with pooled antimalaria monoclonals (3DI 1, 2G3, 2A10), 5 jsg/ml each. After rotation at 00C for 30 min, immune complexes were precipitated by addition of 100 Al of protein A-agarose suspension and centrifugation. After washing twice in 15 mM NaCl, 9 mM EDTA, 50 mM Tris, pH 7.4, containing 0.05% NP40, transfer to new tubes, and washing again in the same buffer, precipitated proteins were eluted by resuspending the agarose beads in 50 Ml of SDS-PAGE loading buffer containing 20% 2-mercaptoethanol, boiling for 3 min, and collection of the supernatants. SDS-PAGE analysis of eluted proteins was carried out on 7.5% slab gels according to the method ofLaemmli (31) . After fixation and drying, autoradiographs ofthe gels were obtained at -70'C with X-Omat XAR-5 film (Eastman Kodak Co., Rochester, NY).
Purification ofAChE-negative Ehu. AChE-negative El' from PNH patients were separated as described in reference 32. 25 Ml ofAEl monoclonal anti-AChE ascites fluid was added to 2 ml ofEbu from the patients (1 X 109 Ehu/ml in PBS) and the mixtures rocked at 20'C for 30 min. The cells were pelleted, washed twice in PBS containing 1% BSA, and mixed with I ml of rabbit anti-mouse IgG. After another incubation at 20'C for 30 min and thorough washing in the same buffer, the cells were loaded onto protein A Sepharose CL-4B (2 X 108 Ehu/ml packed gel) equilibrated at 20'C in PBS. The column was opened and unbound cells collected by washing with 1 ml of PBS followed by PBS containing 1% BSA.
Patients. PNH patients were followed at Duke University Medical Center. All had consistent clinical presentations and characteristic abnormalities of their Ehu in the Ham and/or CLS assays.
Results
Relationship between deficiencies ofDAF and ofAChE in PNH E"'. Recent In the first series ofexperiments, the distributions ofthe two defects in PNH II and PNH III E h, were examined by purifying AChE-negative EhU from patients by cell-affinity chromatography (see Methods) and assaying them for DAF content by two-site radioimmunometric assay employing anti-DAF monoclonals. Table I shows the results in relation to DAF levels measured in unseparated Eh" from the same patients. In all eight patients studied, DAF levels in the purified AChE-negative cell populations were zero, indicating that the DAF and AChE deficits in PNH coincide in the same cells. PNH II and PNH III AChEnegative Ehu were both totally DAF-deficient, indicating that the differences in complement sensitivity between these two classes of PNH E U do not reflect differences in DAF contents. DAF levels in the AChE-positive (adherent) Ehu subpopulation from each of the patients were calculated by dividing the total DAF (Fig. 1 B) with respect to extent of DAF deficiency, both coinciding with the negative controls. Purified AChE-negative cells from the latter patient ( Fig. 1 C) comprised a single population containing no DAF-bearing cells. Control studies with anti-AChE monpclofials revealed no AChE-positive Ehu. Identical results were obtained in FACS analyses of AChEnegative Ehu from all other patients studied.
The relationship between the proteins responsible for AChE and DAF activities was next examined in studies employing anti-DAF and anti-AChE monoclonals. First, structural studies were performed. Normal Ehu were surface-labeled with 1231, and the washed stroma extracted with 1% NP40. Aliquots of the extract were immunoprecipitated with pooled monoclonal antiAChE, anti-DAF, or nonrelevant (antimalaria) antibodies, and immunoprecipitated proteins were analyzed by SDS-PAGE followed by radioautography. As shown in Fig. 2 , the anti-AChE and anti-DAF monoclonals precipitated distinct proteins that differed slightly in apparent Mr. Parallel studies with neuraminidase-pretreated Ehu revealed a decrease in the apparent Mr of DAF but not ofAChE. In a second set ofexperiments functional analyses were carried out. Preincubation of the normal EhuAC14 with polyclonal (100 ,g/ml IgG) or pooled monoclonal (1-00 sg/ ml each) anti-AChE antibodies had no effect on the ability of the cells to restrict C4b2a assembly and subsequent lysis upon addition ofhuman C2 and heterologous guinea pig C3-9 (a source of terminal pathway components not inhibited by human cell factors which can be used to assay uptake of autologous C3b [13, 14] ,g/ml each), anti-AChE monoclonals (10-100 gg/ml each), or anti-DAF and anti-AChE monoclonals together, or with polyclonal anti-DAF or anti-AChE antibodies (10-100 gg/ml IgG), separately or in combination, followed by addition of human C5-9 did not induce lysis, indicating that the resistance of the C3b-bearing normal Ehu in human C5-9 (13, 14) is mediated by another entity. In accordance with previous findings (15, 16) that PNH EhU lack this terminal pathway resistance, EhUAC1423 prepared with PNH III E"u and bearing < 2,000 autologous C3b per cell rapidly lysed upon exposure to the human C5-9 (not shown).
The effects of DAF reconstitution on the relative sensitivities ofPNH II and III cells in the CLS assay and on the susceptibility of PNH III cells to passive lysis in the presence of cobra venom factor-treated serum were next examined. Unfractionated or affinity-purified AChE-negative PNH EhU were reconstituted with DAF or incubated with NP40 detergent as control. Fig. 1 , Cand D show FACS profiles of AChE-negative cells from one of the patients (G.R.), before and after the DAF reconstitution. In this case employing purified AChE-negative cells, an increase in anti-DAF fluorescence of the entire DAF-negative cell population occurred. With unfractionated EhU, the uptakes of DAF into DAF-deficient and into DAF-cpntaining cell populations were comparable (not shown) suggesting that affected PNH Ehu are not abnormal with respect to their ability to accept DAF.
To establish that DAF molecules incorporated after DAF reconstitution ofthe PNH cells were functional, the DAF-treated PNH EhU were tested for their ability to restrict assembly of autologous C4b2a (12) . The results of two representative experiments are shown in Fig. 3 . In studies with normal Ehu (Fig. 3  A) , despite > 14,000 C4b per cell, no lysis occurred upon incubation of the cells with C2 followed by guinea pig C3-9 (the developing reagent used to assay C4b2a assembly and function). In contrast, significant lysis ofthe control PNH cells was observed with < 1,000 C4b per cell, whether AChE-negative (Fig. 3, A and B) or unfractionated EhU (Fig. 3 B) were used. After treatment with DAF, the capacity of the PNH cells to circumvent C4b2a assembly was almost completely restored. Measurements with the two-site immunoradiometric assay showed that 344 DAF (Fig. 3 A) and 600 DAF (Fig. 3 B) molecules per cell had incorporated, respectively. The efficiency of the incorporated DAF in inhibiting C4b2a assembly was comparable to that observed in previous studies (8, 12) . The incorporated DAF was thus fully functional. The effect of the incorporated DAF on the sensitivity of the PNH cells in the CLS assay was next examined. The results pf one study with PNH II cells are illustrated in Fig. 4 . Restoration ofDAF activity to PNH II E"" (Fig. 4 A) reduced their sensitivity in CLS to near normal levels. Conversely (Fig. 4 B) , treatment of normal EhU with polyclonal anti-DAF antibodies (30 .g/ml IgG) increased their sensitivity in CLS to the level of PNH II cells. Augmenting the concentration of anti-DAF antibody 3-or 10-fold further (to 300 ,g/ml IgG) had no additional effect.
In contrast, in multiple studies (see Table II ), DAF reconstitution had only a minimal effect (< 30% reduction) on the sensitivity of PNH III cells in CLS (Fig. 5) (Table III) . The effect of DAF reconstitution of PNH III Ehu on the sensitivity of PNH III cells to passive lysis in cobra venom factortreated human serum was next evaluated. The results of a typical study are shown in Fig. 6 . Significant lysis of PNH III E'u occurred in 1/64 cobra venom factor-treated serum, whereas minimal lysis of normal Ehu occurred in 1/8 cobra venom factortreated serum. Reconstitution of the PNH cells with DAF did not diminish their sensitivity to lysis in this assay. Conversely, prior treatment of the normal cells with polyclonal anti-DAF antibodies (30-300 ,ug/Mrl IgG) did not abrogate their inherent resistance. In three other studies with both unfractionated and purified AChE-negative cells (Table II) , incorporation of up to 585 DAF molecules per cell (the maximal attainable DAF level with the reagents used) had no effect. The inability of DAF to influence this terminal pathway defect under conditions in which inhibition of C3 convertase assembly was restored argues that a third abnormality ofthe membrane must exist in PNH III cells.
The evaluation of DAF levels in AChE-positive Ehu of the PN} patients by calculation from immunoradiometric data had indicated that complement-insensitive (PNH I) Ehu are partially DAF-deficient (Table I ). In the final series of studies, 'comple- $ Ebu (from patient G.R.) were incubated at 30'C for 10 h with decreasing dilutions of either DAF-NP40 or NP40 alone in isoionic veronal buffer. After washing, the treated cells were assayed for CLS as described in Methods. Normal range <2 U.
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were selectively lysed with cobra venom factor-treated serum, and the remaining complement-insensitive PNH I E"" examined directly for DAF and AChE expression by flow cytometry. The results are shown in Fig. 7 . Fig. 7, A One problem that has complicated the characterization of these and other membrane alterations that have been described in PNH (1) has been the mixture in the blood of PNH patients of complement-sensitive and complement-insensitive cell populations. Separation of AChE-negative Ehu subpopulations by cell-affinity chromatography in the present study, and examination ofthe purified cells by radioimmunometric assays (Table  I) and by FACS analyses (Fig. 1 (4, 35) . In contrast to the abnormalities of the above three factors, the reduction in CR1 expression was only partial. Moreover, differently from the defects in the above factors, it was similarly distributed between complement-sensitive and -insensitive Ehu populations. These findings raise the possibility that the CR1 defect may arise secondarily. Levels of Ehu-associated CR1 are diminished in conditions associated with heightened activity of the complement system and the extent of the reduction is reciprocally related to acquisition of C3 activation fragments on the cells (35, 36) . Increased levels of such fragments have been detected on PNH Ehu (35) , suggesting that the CR1 defect in PNH might likewise arise as a consequence of increased rates of complement activation in PNH blood. Such a mechanism could account for the presence of the defect in both complement-sensitive and -insensitive Ehu populations.
Although the use ofthe anti-DAF (2-4) and anti-AChE (32) antibodies has demonstrated that the -70-kD proteins associated with these two functional activities are deficient in PNH Ehu, it has not been previously established whether the two defects are due to different abnormalities. The selective immunoprecipitation of DAF and AChE by the respective monoclonals (Fig. 2) unequivocally demonstrates that they are in fact different proteins (37) and avoids uncertainties arising from interference by anti-glycophorin antibodies within polyclonal anti-DAF antisera (38) . Although association ofthe two proteins in the membrane of intact Ehu cannot be excluded, their lack of coprecipitation argues that they are not anchored in the membrane covalently by a common linking molecule. The limitation of the inhibitory effects of anti-AChE and anti-DAF antibodies to the activities associated with their respective antigens on normal Ehu and the failure of DAF reconstitution to augment AChE activity in PNH Ehu indicate that the functional activities of AChE and DAF in Ehu membranes are independently mediated.
PNH III E'u are characterized by their abnormal susceptibility to reactive lysis in addition to their exaggerated uptake of C3b (1, 15, 16) . This functional defect is due to an inability of their membranes to circumvent damage by the membrane attack complex, according to current evidence, at the level of C9 (13, 14) . The relationship of this defect, however, to DAF deficiency previously was not clarified. It has been suggested that the greater passive lysis susceptibility of PNH III than PNH II E"u could be due to more profound DAF-deficiency in the PNH III cells (3, 11) . Of relevance, it has been reported that cell-bound C3b might enhance C9 insertion, providing a potential mechanism for a DAF effect (14) . Several findings in the present study argue against this possibility and provide strong support for the alternative suggestion (39) that the two phenomena are mediated by different mechanisms. Analysis of purified AChE-negative PNH II and PNH III E"u by radioimmunometric assay and flow cytometry revealed that both are totally DAF-deficient (Table I , Fig. 1 ) suggesting that an additional defect must be present in the PNH III cells. Despite abrogation of DAF activity as evidenced by uptake of 10,000 C3b molecules by the cells and brisk lysis in heterologous guinea pig C5-9, anti-DAF treatment of normal EhUAC 1423 did not render the intermediates susceptible to lysis in homologous C5-9. Similarly, exposure of normal EhU to 10-fold higher concentrations of anti-DAF antibodies than necessary to overcome resistance to C3 convertase assembly (12) increased the sensitivity of the normal cells in the CLS assay only three-to fivefold (to that of PNH II Eh') (Fig. 4) , and did not render the cells susceptible to passive lysis in cobra venom factor-treated human serum (Fig. 6) . Finally, reconstitution of PNH III E'u with DAF in amounts sufficient to restore their ability to restrict C4b2a assembly (12) reduced their sensitivity in CLS by < 30% (Fig. 5) and had no discernable effect on their vulnerability to passive lysis (Fig. 6) with the ability to bind to C8 and block its interaction with C9 has been isolated from extracts of Ehu stroma by Schonermark et al. (41) . The relationship, however, of this factor to the above inhibitors of C9 polymerization has not yet been investigated.
The demonstration in this study that the characteristic abnormalities ofPNH are a result ofdeficiencies in multiple membrane components rather than in DAF alone has important implications concerning the mechanism of the PNH defect. Previous findings that small amounts ofDAF antigen are detectable in affected leukocytes of patients (9) and that, when cultured in vitro, DAF-positive erythroid precursors in patients' marrow give rise to DAF-negative erythroid colonies (42) suggest that the diminished DAF expression in PNH is not due to absence or nonfunction of the DAF structural gene. That deficient expression of the factors does not arise from the failure of PNH membranes to hold the factors or to support their function is indicated by the ability of exogenous DAF to incorporate into PNH Ehu and to restore the resistance ofthe affected cells to C3 convertase assembly (12) . The simultaneous deficiency of the three entities could arise from a biosynthetic defect in a structural element shared by the three factors. Structural analyses of Ehu AChE and DAF have revealed the presence ofa covalently linked glycolipid at the COOH-terminus of each molecule rather than hydrophobic amino acids typical of conventional membrane polypeptide anchors (43-47). This non-amino acid anchor is comprised of fatty acids, inositol, and an oligosaccharide and is closely similar in both proteins (48) . In AChE, this anchoring structure has been shown to be linked through an ethanolamine to the COOH-terminal amino acid ofAChE polypeptide and in studies of DAF, there is evidence that it is incorporated posttranslationally before addition of O-linked sugars to DAF in the Golgi. If the putative terminal pathway inhibitory molecule shares the same glycolipid anchoring structure, a defect in the assembly of this structure or its attachment to the respective proteins could lead to deficient expression of all three molecules.
A biosynthetic defect in a structure common to the proteins, however, would not account for the sporadic occurrence of defects in only two of the factors and thereby would not explain the findings in the present study that PNH II and PNH III E"u 172 differ with respect to the absence or presence of a defect in terminal pathway restriction (Figs. 5 and 6 ). It is possible that different biosynthetic defects could give rise to the two classes of PNH cells. It is alternatively possible that PNH involves a regulatory rather than a biosynthetic defect and that expression of DAF and AChE and expression of the entity responsible for terminal pathway restriction are independently controlled. Recent findings that normal platelets manifest DAF activity (9, 10, 49) but not terminal pathway restriction (49) support this possibility. In either case, it would not be surprising if more than one alteration could lead to DAF deficiency and the consequent clinical expression of PNH and if the changes that characterize PNH II and III cells could arise by different mechanisms.
Current evidence indicates that PNH is a clonal disorder (1). For this and other reasons, it has been assumed that the complement-insensitive (PNH I) Ehu in PNH blood are products of natural hematopoiesis and remain entirely normal. Our observation that DAF and AChE levels are reduced in the PNH I cells of most patients (Table I and Fig. 7 ) raises the possibility that PNH I cells could also derive from abnormal progenitors. Alternatively, it is possible that their DAF alterations could arise secondarily as a consequence of effects of the DAF-deficient Ehu population on them in the circulation (or on their precursors in the marrow) or as a result of the complement dysregulation that occurs in PNH blood.
